The Phase 1b/2a clinical trial (NCT04445831), which was sponsored by AC Immune SA (clinical-stage biopharmaceutical company), examined the safety, tolerability, and immunogenicity of two tau-targeted liposomal vaccines, namely ACI-35.030 and JACI-35.054, in the early stages of AD
Krystel-Whittemore, M., Dileepan, K
Wegovy titrates up to 2.4 mg weekly, while Ozempic is approved for up to 2.0 mg
Build around one primary peptide, then add support ingredients that improve hydration, comfort, and consistency of use
An imbalance of T H 1/T H 2-cell responses is thought to contribute to the pathogenesis of various infections, allergic responses and autoimmune diseases
32 PerezF.HujerA